Gilead Faces Challenges In HCV, But Competitors Would Switch Places
Executive Summary
Merck is pursuing a patient-access strategy in HCV with newly approved Zepatier, while AbbVie is acknowledging lower-than-projected 2015 sales for Viekira Pak but expressing optimism about competing in the space.